Article Sidebar

PDF
Date Published: 20/06/2023
Abstract Views: 3284
Views PDF: 2670
DOI: https://doi.org/10.59873/vjid.v2i42.268
Issue
Vol. 2 No. 42 (2023): WARM WELCOME TO THE SECOND EXPANSIONAL SCIENTIFIC CONFERENCE ON INFECTIOUS DISEASES AND TROPICAL DISEASES IN THE CENTRAL REGION AND THE WEST HIGHLAND OF VIETNAM IN YEAR 2023
Section
Scientific research
How to Cite
Tran, X. C. (2023). UPDATE OF HCV TREATMENT (2023). Vietnam Journal of Infectious Diseases, 2(42), 2-5. https://doi.org/10.59873/vjid.v2i42.268

UPDATE OF HCV TREATMENT (2023)

Xuan Chuong Tran

Main Article Content

Abstract

Viral hepatitis C has a significant impact on morbidity and mortality worldwide as it is a cause of cirrhosis, hepatocellular carcinoma, liver transplantation, and liver-related deaths. The current global HCV prevalence estimate is 1%, corresponding to 71 million infected people. In Vietnam, WHO’s research (2019) estimates that more than 1 million people are infected with HCV.


Current screening strategies mainly target people at high risk of HCV infection: people who inject drugs, have a family member infected with HCV, patients undergoing hemodialysis, ect. Current medicines (DAAs) are all proven to be highly effective, safe and can be used for all hepatitis C patients. The duration of treatment is short, the drug is well tolerated, and even the patient's with decompensated cirrhosis or underlying medical conditions can also be treated. The World Health Organization (WHO) has approved the Global Strategy to eliminate HCV infection by 2030. This review presents the latest WHO and AASLD recommendations on strategies for diagnosis, treatment and treatment of hepatitis C in special subjects.

Article Details

Keywords

Viral hepatitis C, treatment

References

1. AASLD-IDSA HCV Guidance Panel Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin. Infect. Dis. 2018;67:1477-1492.
2. Chayan Bhattacharjee, Maitri Singh, Debisukti Das, Aparna Mukhopadhyay, Current therapeutics against HCV, Virus Dis. (April-June 2021) 32(2):228-243.
3. European Union HCV Collaborators Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: A modelling study. Lancet Gastroenterol. Hepatol. 2017;2:325-336. doi: 10.1016/S2468-1253(17)30045-6.
4. European Association for the Study of the Liver, EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol. 2020;73:1170-1218. doi: 10.1016/j.jhep.2020.08.018.
5. Lorenza Di Marco,1,2 Claudia La Mantia,3 and Vito Di Marco3,*, Hepatitis C: Standard of Treatment and What to Do for Global Elimination, Viruses. 2022 Mar; 14(3): 505.
6. Reau N., Kwo P.Y., Rhee S., Jr R.S.B., Agarwal K., Angus P., Gane E., Kao J., Mantry P.S., Mutimer D., et al. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients with Hepatitis C Virus Infection. Hepatology. 2018;68:1298-1307.
7. WHO . Combating Hepatitis B and C to Reach Elimination by 2030. World Health Organization; Geneva, Switzerland: 2016.
8. WHO . Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version. World Health Organization; Geneva, Switzerland: 2016.